SkinVision Pro Bridges Diagnostic Gap Between Home and Clinic

The platform, known as SkinVision Pro, addresses the lack of context that often hampers initial dermatological consultations. By enabling patients to perform AI-driven skin assessments at home, the system creates a digital bridge between the patient and their GP. The clinic receives a structured dashboard containing the lesion’s image, reported symptoms, and the AI’s risk assessment, effectively triaging cases before the physical appointment occurs.

Clinically, the underlying technology holds a CE Class IIa medical device certification, boasting over 90% sensitivity and 89% specificity for skin cancer detection. Early data from the first quarter of 2026 in Dutch primary care settings indicates that 80% of users received a low-risk result and were reassured at home, potentially reducing unnecessary clinic visits. Conversely, 24% of those flagged as high-risk by the system received a confirmed cancer diagnosis, validating the tool’s utility in identifying urgent cases.

Erik de Heus, CEO of SkinVision, noted that skin conditions represent roughly 15% of all GP consultations. By automating the intake process, the platform aims to streamline the primary care pathway. To support implementation, the company is offering an early adopter package that includes staff training via SkinVision Academy and ready-to-use patient onboarding materials, ensuring the software integrates into existing clinical systems without creating an administrative bottleneck.